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An early and sizeable loss of basal forebrain cholinergic neurons is a well-characterized feature associated with measurable deficits
in spatial learning and cognitive impairment in patients with Alzheimer’s disease. In addition, pro-inflammatory glial cells such as
astrocytes and microglia may play a key role in the neurodegenerative cascade of Alzheimer’s disease and tauopathies. We recently
presented two mouse models: Line 1, expressing the truncated tau fragment identified as the core of the Alzheimer’s paired helical
filament, and Line 66, expressing full-length human tau carrying a double mutation (P301S and G335D). Line 1 mice have a path-
ology that is akin to Alzheimer’s, whilst Line 66 resembles frontotemporal lobar degeneration. However, their cholinergic and in-
flammatory phenotypes remain elusive. We performed histological evaluation of choline acetyltransferase, acetylcholinesterase, p75
neurotrophin receptor, microglial ionized calcium binding adaptor molecule 1 and astrocytic glial fibrillary acidic protein in the
basal forebrain, hippocampus and cortex of these models. A significant lowering of choline acetyltransferase-positive neurons and
p75-positive neurons in the basal forebrain of Line 1 at 3, 6 and 9 months was observed in two independent studies, alongside a
significant decrease in acetylcholinesterase staining in the cortex and hippocampus. The reductions in choline acetyltransferase
positivity varied between 30% and 50% at an age when Line 1 mice show spatial learning impairments. Furthermore, an increase
in microglial ionized calcium binding adaptor molecule 1 staining was observed in the basal forebrain, hippocampus and entorhinal
cortex of Line 1 at 6 months. Line 66 mice displayed an intact cholinergic basal forebrain, and no difference in p75-positive neu-
rons at 3 or 9 months. In addition, Line 66 exhibited significant microglial ionized calcium binding adaptor molecule 1 increase in
the basal forebrain and hippocampus, suggesting a prominent neuroinflammatory profile. Increased concentrations of microglial
interleukin-1b and astrocytic complement 3 were also seen in the hippocampus of both Line 1 and Line 66. The cholinergic deficit
in Line 1 mice confirms the Alzheimer’s disease-like phenotype in Line 1 mice, whilst Line 66 revealed no measurable change in
total cholinergic expression, a phenotypic trait of frontotemporal lobar degeneration. These two transgenic lines are therefore suit-
able for discriminating mechanistic underpinnings between the Alzheimer’s and frontotemporal lobar degeneration-like phenotypes
of these mice.
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Introduction
Tauopathies are a diverse group of neurodegenerative dis-
orders associated with cognitive and behavioural impair-
ments in the ageing population. The most prevalent,
Alzheimer’s disease, is a complex and heterogeneous neu-
rodegenerative disease of the CNS, first presented by
German psychiatrist Alois Alzheimer (Alzheimer, 1907),
typically characterized by the deposition of extracellular
b-amyloid plaques and intracellular tau neurofibrillary tan-
gles (NFTs). Tau is a low-molecular-weight microtubule-
associated protein, expressed predominantly in axons
(Buee et al., 2000) and also dendrites (Ittner and Ittner,
2018). Tau regulates the assembly and stability of microtu-
bules, and its microtubule-binding function is regulated
negatively through phosphorylation (Weingarten et al.,
1975). In Alzheimer’s disease, tau accumulates as NFTs
and ultimately into paired helical filaments. The core of
the paired helical filament is composed of a truncated 95-
amino-acid fragment of tau (Wischik et al., 1988) and is
capable of catalytic conversion of normal soluble tau into
intracellular oligomeric aggregates (Wischik et al., 1995,
1996), resulting in dystrophic neurites, dendrites and cell
bodies, a characteristic pathology of tauopathies (Spires-
Jones et al., 2009). The role of phosphorylation in this
process remains unknown (Kimura et al., 2018).
A significant loss of up to 50% of basal forebrain cho-
linergic neurons is another well-characterized feature of
Alzheimer’s disease (Davies and Maloney, 1976; Perry
et al., 1985). Acetylcholine plays a crucial role in the per-
ipheral nervous system and central nervous system and
can be measured by the presence of neuronal choline ace-
tyltransferase (ChAT; Nagai et al., 1983). In addition, an
age-dependent decline in acetylcholinesterase (AChE), the
enzyme responsible for acetylcholine hydrolysis (Ferreira-
Vieira et al., 2016), is associated with reduced AChE in
patients with Alzheimer’s disease (Hirano et al., 2012;
Janeczek et al., 2018). As such, current symptomatic
Alzheimer’s disease treatments, specifically AChE inhibi-
tors donepezil and rivastigmine, act to remediate this cho-
linergic dysfunction through increasing the level of
acetylcholine at the synaptic cleft (Raina et al., 2008).
Intriguingly, cholinergic degeneration is lacking in fron-
totemporal lobar degeneration (FTLD), a progressive neu-
rodegenerative tauopathy primarily affecting the frontal
and temporal lobes of the brain (Wilkinson et al., 2002;
Roy et al., 2016). This has further strengthened the argu-
ment favourably towards the ‘Cholinergic Hypothesis’ of
Alzheimer’s disease (Terry and Buccafusco, 2003) and is
supported by histological post-mortem studies showing
that low-affinity p75 neurotrophin receptor (p75NTR), a
marker of cholinergic basal forebrain neurons, is signifi-
cantly reduced in mild cognitive impairment (Mufson
et al., 2002). Therefore, an in-depth understanding of the
cholinergic system is key to deciphering the pathological
dissociation between Alzheimer’s disease and other
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tauopathies. The basal forebrain cholinergic system is
composed of the medial septum (MS), horizontal limb of
the diagonal band of Broca (HDB) and vertical limb
of the diagonal band of Broca (VDB), nucleus basalis of
Meynert (classified as the nucleus basalis magnocellularis
in the murine brain; nBM), nucleus accumbens and the
substantia innominata (Niewiadomska et al., 2009). As a
network, these regions provide the major cholinergic pro-
jections via the septo-hippocampal pathway to the ento-
rhinal cortex (EC) and hippocampus, regions that exhibit
parallel tau pathology (Niewiadomska et al., 2006).
Afferent cholinergic projections from the MS to hippo-
campus have been shown as a critical pathway in media-
ting spatial and mnemonic function (Robinson et al.,
2010; Deiana et al; 2011; Okada et al., 2015).
Several tau transgenic (Tg) mouse models have been
generated (Götz et al., 2001; Yanamandra et al., 2015)
to explain the pathogenic mechanisms of tau and to as-
sess the efficacy of therapeutic targets for Alzheimer’s dis-
ease and FTLD. Familial autosomal dominantly inherited
MAPT mutations provide a basis for the majority of tau
Tg mouse models generated to date. These include a tau
Tg mouse that overexpresses tau carrying the mutation
P301L (Götz et al., 2001), a mutation associated with
FTLD (Caillet-Boudin et al., 2015). Overexpression of
human P301L tau in cortical and hippocampal neurons
increases astrocytosis in addition to neuronal apoptosis,
similar to those observed in human tauopathies (Götz
et al., 2001). Alternative approaches to the P301L model
have explored the overexpression of human wild-type
(WT) tau in mice, observing synapse loss and microglial
activation, in some cases even preceding the deposition of
intracellular NFTs (Yoshiyama et al., 2007). A limitation
of the P301L model is that these animals exhibit motor
deficits and hind limb paralysis, traits that are not con-
sistent with symptoms observed in patients with
Alzheimer’s disease. Also, microglial activation without
the appearance of NFT pathology can frequently be
observed in these mice (Götz et al., 2001), presenting a
model lacking true translational features.
The cholinergic Alzheimer’s disease-like dysfunction has
been characterized for several Tg rodent tau models,
most recently in the THY-Tau22 mouse, a model that
displayed major hippocampal Alzheimer’s disease-like tau
pathology within the septo-hippocampal pathway (Belarbi
et al., 2009). This model also presented a significant re-
duction in ChAT-immunoreactive neurons in the MS.
Furthermore, an age-dependant mild astrogliosis was
reported in THY-Tau22 mice, particularly in association
with tau-positive cells (Schindowski et al., 2006).
A pro-inflammatory activation of microglia and astro-
cytes has recently been identified to play a key role in
acting as secondary effector in neurodegenerative cascades
in the human brain, with neuroinflammation considered
to precede the onset of both Alzheimer’s disease and
FTLD symptoms in patients (Heneka et al., 2014;
Morales et al., 2014). This is consistent with observations
in P301L tau Tg mice (Götz et al., 2001). In patients
with Alzheimer’s disease, a strong correlation exists be-
tween NFT deposition and density of activated microglia,
typically established through immunohistochemical stain-
ing of the ionized calcium binding adaptor molecule 1
(Iba1), a robust marker of neuroinflammation (Arends
et al., 2000). In addition, increased inflammatory media-
tors, such as tumour necrosis factor alpha and interleu-
kin-1 beta (IL-1b), are correlated with cognitive deficits
for patients with late-stage Alzheimer’s disease
(Morimoto et al., 2011). In particular, sustained IL-1b
overexpression secreted by activated microglia is known
to exacerbate tau pathology in tau-overexpressing mice
(Ghosh et al., 2013) and up-regulation of complement
C3 protein, a marker of activated A1 astrocytes, has
been observed in PS19 mice in response to NFT path-
ology (Litvinchuk et al., 2017).
Current animal models of tauopathy and Alzheimer’s
disease fail to address the specific molecular mechanisms
by which products of inflammation produced through
activated microglia and astrocytes can induce Alzheimer’s
disease neurodegeneration and the potential link between
the observed cholinergic basal forebrain degeneration.
Therefore, we conducted a robust evaluation of the cho-
linergic system of Line 1 (L1) and Line 66 (L66) Tg mice
to decipher the phenotypic differences in these two genet-
ically distinct models. Given the pathological and behav-
ioural phenotypes previously described in these models
(Melis et al., 2015), the cholinergic phenotypes were per-
formed in two independent studies undertaken in
Warsaw, Poland, and Aberdeen, UK, alongside a robust
evaluation of the neuroinflammatory phenotype of these
two Tg mouse models.
Materials and Methods
Tg animals
Female homozygous Tg L1, L66 and WT NMRI litters
were generated as previously described (Melis et al.,
2015). All animals were bred commercially at Charles
River, UK, and distributed to the respective facilities
(road for Aberdeen, air-freight for Warsaw) 1 month
prior to use to allow ample acclimatization. Animals
were colony housed (up to four per cage) in wire-lid
cages (Makrolon II) on corn cob bedding and enrichment
(paper strips and cardboard tubes) in a controlled facility
(temperature 20–22C, 60–65% humidity, air changes:
17–20 changes per hour) and ad libitum access to water
and food pellets and under a 12-h light/dark cycle (lights
on at 07:00 am). Experiments were carried out in accord-
ance with the European Communities Council Directive
(63/2010/EU), a project licence with local ethical approv-
al under the UK Animals (Scientific Procedures) Act
(1986), or with approval from First Warsaw Local Ethics
Committee for Animal Experimentation, and carried out
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in accordance with Polish Law on the Protection of
Animals and National Institute of Health’s Guide for
Care and Use of Laboratory Animals (Publication No.
85-23, revised 1985).
Immunohistochemistry
Brains were processed independently from mice aged 3, 9 and
12 months (62 weeks) in Warsaw, Poland, and at 6 months
(62 weeks) in Aberdeen, UK. Immunohistochemical analyses
were carried out in independent studies in Aberdeen, UK
[ChAT, Iba1, glial fibrillary acidic protein (GFAP)], and
Warsaw, Poland (ChAT, p75NTR, AChE).
Fluorescent immunohistochemistry for ChAT, Iba1
and GFAP (Aberdeen)
Adult female homozygous 6-month-old Tg L1, L66 and
WT NMRI mice were randomly selected for terminal
intraperitoneal injection of pentobarbital (Euthatal;
0.2 ml/30 g body weight; Merial Animal Health Ltd,
Lyon, France). Anaesthetized mice were transcardially
perfused with 0.9% (w/v) saline, followed by 4% paraf-
ormaldehyde (Sigma-Aldrich, UK) until fixation was
achieved. Skulls were immediately dissected, and whole
brains removed and post-fixed in 4% paraformaldehyde
(4 h), followed by 24 h incubation in 10% sucrose
(Phosphate buffered saline (PBS); pH¼ 7.4), 30% sucrose
(PBS) and 2% DMSO/2% glycerol (Sigma-Aldrich) at
4C over 3 days. Following post-fixation, brains were
snap-frozen in isopentane (2-methylbutane; Sigma-
Aldrich).
Free-floating sections were used from whole brains
embedded in OCT matrix (CellPath Ltd, Newtown, UK).
Coronal sections (30 mm) were obtained (CM1850
Cryostat; Leica Biosystems) from brain regions of interest
[‘Bregma 1.4’; ‘Bregma 3.64 mm’, according to Paxinos
and Franklin (2001)] and stored in cryoprotectant solu-
tion (glycerol, ethylene glycol, 0.1 M PB, 1:1:2) until
staining. Every second section (nBM, VDB) or every third
section [MS, HDB, striatum (ST), EC, CA1, hilus, granu-
lar layer, sub-granular zone (SGZ) and molecular layer of
dentate gyrus (DG)] was stained (3 sections in total).
Sections were blocked in 1% milk powder, 2% bovine
serum albumin (BSA), 0.3% Triton X-II, 1.5% normal
goat serum (ChemiconV
R
) or 5% normal donkey serum
(Sigma-Aldrich) for 1 h at room temperature (RT), rock-
ing. Followed by 3  5 min PBS washes, sections were
incubated in primary antibody, diluted in PBS containing
2% BSA, 0.3% Triton X-II, 1.5% normal goat serum or
5% normal donkey serum to working concentrations
(Supplementary Table 1) overnight at 4C, and the follow-
ing day for 1 h at RT. Sections were washed (3  5 min,
PBS) before incubation (1 h, RT) with secondary anti-
body, containing 2% BSA and PBS, diluted to working
concentrations. Serial sections were mounted onto slides
(VWRV
R
SuperFrost Microscope Slides, 1-mm thick;
Borosilicate glass coverslips, 22 mm  50 mm, VWRVR
International), using ProLong Gold Antifade Mountant
with 40,6-diamidino-2-phenylindole (Thermo Fisher
Scientific, UK) for nuclear staining.
HRP-enhanced immunohistochemistry of ChATand
p75NTR (Warsaw)
Female, homozygous L1, L66 and WT (NMRI) mice at 3
and 9 months were terminally anaesthetized with pento-
barbital (Morbital; 1.7 ml/kg) by intraperitoneal injection.
Mice were subsequently perfused with 0.01 M PBSV with
0.05% heparin (w/v) and then with 4% paraformalde-
hyde containing 15% saturated picric acid for fixation
and cryopreserved in 5% glycerol/2% DMSO (0.1 M
PBSV, pH¼ 7.4). Whole brains were dissected and post-
fixed in 4% paraformaldehyde (12 h), followed by a 24 h
incubation in 10% glycerol/2% DMSO (0.1 M PBS,
pH¼ 7.4; 1 mM Na3VO4; PBSV) and 20% glycerol/2%
DMSO (PBSV), over 3 days. After post-fixation, brains
were snap-frozen on dry ice and stored in 80C until
staining. Whole brains were embedded in ShandonTM
CryomatrixTM embedding resin (Thermo Fisher Scientific,
USA) and sectioned at 40 mm. Free-floating sections were
washed in 0.1 M PBSV (3  5 min) and incubated with
1% H2O2 (Chempur, Poland) for 30 min to block en-
dogenous peroxidases. Sections were blocked in a serum
solution [5% normal rabbit serum (Vector Laboratories,
USA) or 5% normal goat serum (Vector Laboratories,
USA) (for ChAT and p75NTR, respectively), 0.3% Triton
X-100 (Sigma-Aldrich, USA) in 0.1 M PBSV]. They were
then incubated in primary antibody (Supplementary Table
1) in blocking solution (1% BSA) for 1 h at RT, and
overnight at 4C. Sections were washed in PBSV (3  5
min) before incubation with secondary antibody (0.1 M
PBSV with 5% normal rabbit serum/5% normal goat
serum, 1% BSA, 0.3% Triton X-100), diluted to working
concentrations (Supplementary Table 1) for 1 h at RT.
Sections were washed (PBSV, 3  5 min) and incubated
with horseradish peroxidase-conjugated streptavidin, 1%
BSA, and PBSV (1:500; Vector Laboratories Inc.).
Following 3  5 min PBSV washes, sections were finally
incubated with 3,30-diaminobenzidine (0.025%) in 0.1 M
PBSV containing 0.04% NiSO4 and 0.025% H2O2. The
reaction was stopped via the addition of 0.1 M PB (pH
7.4). After 3  5 min washes (0.1 M PB), sections were
mounted onto glass slides, allowed to dry, before immer-
sion in xylene, and mounted in DePeX.
Enzyme-linked immunosorbent
assay of IL-1b and C3
Adult female homozygous 6-month-old L1, L66 Tg mice
and WT NMRI mice were decapitated and the ST (with
nucleus accumbens) and hippocampus collected and
stored at 80C, until further use. Concentrations of IL-
1b (n¼ 3) and complement 3 (C3, n¼ 5) were quantified
by enzyme-linked immunosorbent assay in regions of
interest (Mouse Interleukin 1beta ELISA Kit,
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MyBioSource, USA; Mouse Complement Component 3
ELISA Kit, MyBioSource, USA), according to manufac-
turer’s instructions, and results expressed in pictograms
per millilitre and micrograms per millilitre, respectively.
All standards and samples were added in duplicate to the
microtiter plate, and the IL-1b and C3 concentrations
were calculated from standard curves.
AChE histochemistry
In accordance with a modified version of Koelle–
Friedenwald method (Koelle and Friedenwald, 1949), air-
dried sections on glass slides were rinsed in double-distilled
water and, to reveal hippocampal or cortex staining,
incubated for 1 or 1.5 h, respectively, at RT, shaking, in
solution (ethopropazine, glycine, CuSO45H2O, acetylthio-
choline iodide, sodium acetate, glacial acetic acid, double-
distilled water). Slides were washed 6  5 min with water
and developed (1.25% sodium sulphide solution) for
1 min. Slides were washed again for 6  5 min with water
and incubated with intensifying solution (1% AgNO3, w/
v) in water, washed 3 5min with water and incubated
again for 2 5 min (5% Na2S2O3, w/v), at RT with shak-
ing. Finally, slides were washed 6  5 min with water be-
fore immersion in xylene and mounted in DePeX.
Quantitative analysis of ChAT, Iba1
and GFAP-IR neurons (Aberdeen)
Fluorescent images of ChAT, Iba1 and GFAP-IR were
obtained under a Zeiss-Axio Imager M1 upright fluores-
cence microscope (Zeiss, Germany). Stereological cell
counting of ChAT-stained neurons was recorded using
the Optical Fractionator method of Stereo Investigator
Stereology Software (MBF Bioscience). Regions were iden-
tified microscopically in accordance with the Mouse
Brain Stereotaxic Atlas (Paxinos and Franklin, 2012) as
MS, nBM the VDB and HDB, the nucleus basalis magno-
cellularis (nBM), ST and EC. Hippocampal regions were
identified as the sub-regions of the DG: hilus, granular
layer, SGZ molecular layer and as CA1 (see
Supplementary Fig. 1). A cell was considered as a cholin-
ergic neuron when the following criteria were reached:
ChAT immunoreactivity of neuronal somata as well as
good visibility of cell nucleus and proximal segment of
two or more dendrites within the counting frame, allow-
ing for the exclusion of neuronal debris. Regions were
outlined using a 2.5 magnification, and cell counting
was carried out using the 20 magnification by an expe-
rienced experimenter. There was no sample blinding.
Quantitative analysis of ChAT-IR
neurons (Warsaw)
Sections were imaged under a Nikon Eclipse Ni-E microscope.
The computerized densitometric image analysis (NIS-
Elements BR4.30.00; Nikon Instruments) of ChAT-IR
neurons was performed in the basal forebrain regions (MS,
VDB, HDB, nBM and ST). Regions were identified micro-
scopically in accordance with the Mouse Brain Stereotaxic
Atlas (Paxinos and Franklin, 2012). Regions of interest were
outlined using the software’s X–Y plotting system that meas-
ures the square area (mm2) of the marked frame, and ChAT-
IR neurons were counted manually at 400 magnification.
Cell counts per section were then corrected with the
Abercrombie’s formula (Abercrombie, 1946), and the pack-
ing density of the cholinergic neurons was calculated as a
function of rostro-caudal level and location within the studied
structures by using the obtained cell counts and the square
area of the marked frames in each analysed section.
Therefore, the mean number of ChAT-IR neurons obtained
from each experimental group was expressed as packing dens-
ity (the number of cells/mm2).
Quantitative analysis of AChE
AChE was analysed microscopically at 100 magnification
using NIS-Elements BR4.30.00 Software. Measurements
were taken from a fixed area of 75 000 6 500 mm2 in the
primary somatosensory cortex and the CA3 hippocampal
area, which comprises a cross-section of all cortical or hip-
pocampal layers. Data are presented as the mean optical
density in Tg L1 or L66 (for both lines n¼ 3) or WT
mice (n¼ 2) at 3 and 12 months of age.
Statistical analysis
All data sets are expressed as group mean 6 SEM for the
number of experiments indicated in the figure and table
legends. Data were analysed using one-way or two-way
ANOVA, followed by post hoc comparison using two-
tailed Student’s t-tests and Newman–Keuls test. Specific
weight was given to the comparison between Tg and WT
mice, but not between Tg lines. The Mann–Whitney U-test
for independent groups was also used, when appropriate.
Differences between groups were considered statistically
significant for *P< 0.05. Statistical analyses were per-
formed using GraphPad Prism 5.04 (Aberdeen, UK) and
STATISTICA 12 software (Warsaw, Poland).
Data availability
All the raw data supporting the results of this study are
available at the reader’s request.
Results
Loss of cholinergic neurons in the
basal forebrain of L1 mice
Immunofluorescence levels of the ChAT enzyme were
determined using two independent experiments using two
immuno-histochemical staining methods in coronal mouse
brain sections of the basal forebrain. Sections from L1
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animals at 3, 6 and 9 months show a clear reduction in
both density and total ChAT-IR neuron cell count in
basal forebrain regions of the MS, nBM, VDB, HDB and
ST, compared to WT brain sections (Figs 1 and 2). A
two-way ANOVA with genotype and age returned a
P< 0.001 for the factor genotype in all regional compari-
sons. This effect was mainly due to significantly reduced
ChAT-IR packing densities in basal forebrain and ST of
L1 (Fig. 1A–E, MS, VDB, HDB, nBM and ST; all P-val-
ues <0.001 compared with WT). In addition, the age fac-
tor was significant only in nBM (P< 0.0001) and in ST
(P< 0.05), but not in MS, VDB or HDB.
In agreement with the above profile, an independent set
of experiments using fluorescence measured total ChAT
cell counts in L1 and L66 at 6 months of age. It con-
firmed reduction in ChAT positivity in L1 for all regions
of the basal forebrain, but not in L66. The reduction for
all regions was between 30% (MS) and 60% (nBM) in
L1 compared to WT (Fig. 2A–E, Supplementary Table 2).
Altered AChE in cortex and
hippocampus of L1 mice
The AChE activity was assessed histochemically from an
area cross-sectioning through all cortical and hippocampal
layers. The staining was visibly weaker in L1 mice com-
pared with WT at 3 and 12 months (Fig. 3). Densely
stained individual cortical layers could not be distinguished
in L1 tissue, whereas WT and L66 exhibited two distinct
bands with high staining intensity corresponding with cor-
tical layers II and V. This was confirmed quantitatively
(Fig. 3C and D). There was also a significant decrease in
AChE staining within cortex of L1 mice compared with
age-matched WT (P< 0.001; Fig. 3C).
AChE staining in hippocampus was lower in L1 relative
to WT (P< 0.001) (Fig. 3D). Conversely, increased AChE
staining intensity was observed in L66 relative to WT
(P< 0.01) probably due to the elevated AChE level in 3-
month L66 mice as compared to age-matched WT.
Moreover, L1 and L66 mice displayed a significant decrease
in AChE staining with age (age factor P< 0.05) (Fig. 3D).
Decreased low-affinity neurotrophin
receptor staining in L1 basal
forebrain
The qualitative immune-histochemical examination of
low-affinity neurotrophin receptor showed a decrease in
both the number of p75NTR-IR neurons and the intensity
of staining in L1 mice in MS, VDB, HDB and nBM in
Figure 1 ChAT staining intensity is reduced in L1 basal forebrain at 3 and 9 months. Representative microphotographs and
quantification of ChAT immunohistochemical staining in the basal forebrain regions of (A) MS, (B) VDB, (C) HDB, (D) nBM and (E) ST in 3- and
9-month-old transgenic L1 (n¼ 3), L66 (n¼ 3) and WT (NMRI; n¼ 3) mice. Images were obtained at a 100 magnification. Scale bar: 200 lm.
Cell counts are expressed as PD of ChAT-IR neurons (N/mm2). The effect of genotype was determined using a two-way ANOVA, with transgene
and age as factors followed by the Newman–Keuls test. Data were considered statistically significant with alpha set to 5%. *P < 0.05, **P < 0.01
and ***P < 0.001. Data presented as mean 6 SEM. PD ¼ packing density; ST ¼ striatum.
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comparison to WT (Fig. 4A–D). This was already present
at 3 months of age, and there was a further decline in
mice at 9 months. In contrast, the p75NTR staining of 3-
month-old L66 mice showed a positive p75NTR-immunor-
eactivity resembling the pattern in WT, with particularly
strong staining in cell bodies and neuropil. In addition, at
9 months, the intensity of p75NTR staining did not seem
to be altered in L66 or WT (Fig. 4).
The quantitative analysis revealed decreased packing density
of p75NTR in L1 mice as compared to WT in all studied struc-
tures (MS, P< 0.001; VDB, P< 0.001; HDB, P< 0.001;
nBM, P< 0.001). In turn, age factor reached significance only
in nBM. In 9-month-old animals of all groups, p75NTR pack-
ing density was elevated as compared to 3 month-old mice and
resembled the pattern seen in ChAT staining.
Increased glial staining in both L1
and L66 basal forebrain
To gain further insight into the neuroinflammatory pro-
file induced by tau overexpression in our Tg models, an
analysis of Iba1 and GFAP-IR was conducted using im-
mune-histochemical fluorescence staining methods. An ini-
tial focus was placed on the basal forebrain regions, for
which a selective decline in ChAT positivity had been
confirmed (see Figs 1 and 2). Areas included MS, nBM,
VDB, HDB and ST.
A significant increase in the density of Iba1-IR was
observed in L1 in VDB and HDB (P < 0.01) and ST
(P< 0.05; Fig. 5B, C and E) at 6 months. The HDB was the
only basal forebrain region, in which a significant increase
in GFAP-IR was seen in L1 (P< 0.05, Fig. 6C,
Supplementary Table 2). A robust increase in Iba1-positive
microglia in L66 animals was observed for all basal fore-
brain regions apart from the nBM (P < 0.01; Fig. 5A–C and
E). In parallel with L1, L66 also displayed a significant in-
crease (P< 0.01) in the density of GFAP-reactive astrocytes
within the HDB (Fig. 6, Supplementary Table 2). It is intri-
guing to note that, despite the robust cholinergic loss of
ChAT in nBM of L1 animals (Figs 1 and 2; Supplementary
Table 2), this was not matched by enhanced inflammatory
responses of either Iba1 or GFAP.
Figure 2 ChAT staining intensity is reduced in L1 basal forebrain at 6 months. Fluorescence microscopic images of ChATexpression
and ChAT stereological cell counting from basal forebrain regions of the (A) MS, (B) VDB, (C) HDB, (D) nBM and (E) ST in L1 (n¼ 4), L66
(n¼ 4) and WT (NMRI, n¼ 3) mice. Representative images were obtained at 2.5 or 20 magnification, as indicated. Scale bar 2.5, 450 mm;
20, 55 mm. Cell counts are expressed as total cells. The effect of genotype was determined using a one-way ANOVA and individual genotype
differences by Student’s t-test. Data were considered statistically significant when *P < 0.05 and **P < 0.01. Data presented as mean 6 SEM. ST
¼ striatum.
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Increased glial immunostaining in
hippocampal sub-regions of both L1
and L66
To evaluate the microglial and astrocyte contribution to the
disease pathogenesis induced by ChAT loss and tau overex-
pression in Tg models L1 and L66, immunohistochemical
fluorescence staining methods were used on coronal mouse
brain sections of the DG (hilus, molecular layer, granular
layer, SGZ), hippocampus and EC. Representative images
displaying selected brain regions for Iba1 and GFAP-IR
counting in the hippocampus proper and DG micro-circuits
are given in Fig. 7A and Supplementary Fig. 1. Robust
microgliosis based on a significant increase in Iba1-IR
Figure 3 Intensity of AChE staining is reduced in L1 cortex and hippocampus. Representative microphotographs of AChE MOD in
cortex (A) and hippocampus (B) of transgenic L1, L66 and WT (NMRI) mice at 3 and 12 months. n¼ 5 for all groups except WT, L66 cortex at
12 months, and WT, L66 hippocampus at 12 months, where n¼ 4 per group. The rectangle represents the area of measurement for the analysis
of MOD in the cortex and hippocampus. Scale bar: 100 lm. MOD of AChE quantified in cortex (C) and hippocampus (D) of transgenic L1, L66
and WT (NMRI) mice at 3 and 12 months. The AChE is presented as MOD þ SEM. Main effects were determined using two-way ANOVA and
the source of significance explored by post hoc Newman–Keuls test. Data were considered statistically significant with alpha set to 5%. *P < 0.05,
**P < 0.01 and ***P < 0.001. Data presented as mean 6 SEM. MOD ¼ mean optical density.
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Figure 4 p75NTR immunohistochemistry in L1 and L66 basal forebrain. Representative microscopic images of p75NTR
immunohistochemical staining and PD of p75-IR neurons (N/mm2) in the basal forebrain regions of (A, E) MS, (B, F) VDB, (C, G) HDB and (D,
H) nBM in 3- and 9-month-old transgenic L1 (n¼ 3) and L66 (n¼ 3) and WT NMRI (n¼ 3) mice. Images were obtained at a 100 magnification.
Scale bar represents 200 lm. The effect of genotype was determined using a two-way ANOVA, with transgene and age as factors followed by
Newman–Keuls test. Data were considered statistically significant with alpha set to 5%. *P < 0.05, **P < 0.01 and ***P < 0.001. Data presented
as mean 6 SEM. PD ¼ packing density.
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density was observed in L1 mice and this was specific to
the SGZ of the DG (SGZ P< 0.001; Fig. 7A, G, H) and
the EC (P< 0.05; Fig. 7C and I). In L66, microgliosis was
more widespread and heightened Iba1 reactivity was
observed in the hilus of the DG, granular layer, SGZ (all
P’s < 0.001), and the EC (P< 0.01), relative to WT mice
(Fig. 7A, C-G, I).
No gliosis was observed in the molecular layer of
the dentate or CA1 in either Tg line confirming the
specificity of inflammatory responses to sub-regions.
As for GFAP-IR astrocyte activation, there was a signifi-
cantly increased density specific to the SGZ in L1 and
L66 (P< 0.05), but not for other areas of the hippocam-
pus (Fig. 7B, H, J, Supplementary Table 2).
Increased concentrations of IL-1b
and C3 in the hippocampus of L1
and L66 mice
Quantitative analysis of complement C3 and IL-1b was
measured in ST with nucleus accumbens and
hippocampus from 6-month-old Tg L1, L66 and WT
(NMRI) mice (Fig. 8). In the ST, there was no difference
in IL-1b and C3 concentrations between NMRI, L1 and
L66 mice (Fig. 8A and C).
In the hippocampus, statistical analysis showed signifi-
cantly higher concentrations of IL-1b and C3 in L1
(P< 0.01 for IL-1b and C3) and L66 mice (P< 0.05 for
IL-1b and P< 0.01 for C3) compared to NMRI controls
(Fig. 8B and D).
Discussion
We report here on the distinct cholinergic and inflamma-
tory phenotypes in the tau Tg mouse models L1 and
L66, observations which permit a strong discrimination
between Alzheimer’s disease-like and FTLD-like pathology
in these mice. These models overexpress two different tau
protein species: truncated paired helical filament-core tau
(L1) and full-length mutant tau (L66) expressed under
the pan neuronal-specific Thy1 promoter. In addition, it
Figure 5 Increased microglia in L1 and L66 mice. Iba1 stereological cell-counting analysis from basal forebrain regions of the (A) MS, (B)
VDB, (C) HDB, (D) nBM and (E) ST in transgenic L1 (n¼ 4), L66 (n¼ 4) and WT (NMRI, n¼ 4) mice at 6 months. Cell counts are expressed as
the density of Iba1-positive cells (cells/mm2). Main effects of genotype were determined by one-way ANOVA, and the source of reliability was
confirmed by post hoc Student’s t-test. Data were considered statistically significant when *P < 0.05, **P < 0.01 and ***P < 0.001. Data presented
as mean 6 SEM. ST ¼ striatum.
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must be mentioned that L66 has an additional endoplas-
mic reticulum targeting signal sequence peptide, which is
lacking in L1 mice (Melis et al, 2015a), albeit this is un-
likely to have any influence on the following phenotypes
reported in this study. Pathologically, mice mimic an
Alzheimer’s disease-like pathology that follows a Braak-
like progression (Braak and Braak, 1995) and features
cognitive impairment (Melis et al., 2015). L66 mice
mimic FTLD-like pathology and feature an early-onset
motor deficit that becomes more severe with age (Melis
et al., 2015).
L1 exhibits features of Alzheimer’s
disease
In the basal forebrain of L1, we observed a significant
loss of cholinergic neurons at 3, 6 and 9 months, com-
pared to control groups, in two independently conducted
studies. Lack of reproducibility between rodent patho-
logical pre-clinical studies is a prevalent issue (Treuting
et al., 2016; Ward et al., 2017). Therefore, these two
independent, parallel studies robustly support this cholin-
ergic phenotype observed in L1 and lack thereof in L66.
In agreement with the Alzheimer’s disease-like pheno-
type of L1, the significant basal forebrain cholinergic neu-
ron loss matches that observed in post-mortem brains of
patients with Alzheimer’s disease (Davies and Maloney,
1976; Whitehouse et al., 1982). Cholinergic afferents of
the MS and VDB project towards the hippocampus via
the septo-hippocampal pathway, and cholinergic somata
in the nBM primarily target the cortical neurons via the
baso-cortical pathways (Khakpai et al., 2013).
Specifically, cholinergic afferents from the MS to hippo-
campus appear crucial in the regulation of spatial and
mnemonic function (Okada et al., 2015). A lowering in
basal forebrain cholinergic ChAT-IR neurons would
therefore contribute to an explanation of the behavioural
age-dependent deficits in episodic-like memory previously
observed in L1 (Melis et al., 2015) and is at the same
time reminiscent of the pathology and cognitive decline
typically at play in Alzheimer’s disease (Grothe et al.,
2010; Pedroso et al., 2018).
Figure 6 Basal forebrain gliosis in both transgenic models. GFAP stereological cell-counting analysis from basal forebrain regions of the
(A) MS, (B) VDB, (C) HDB and (D) nBM; (E) ST, in transgenic L1 (n¼ 4), L66 (n¼ 4) and WT (NMRI, n¼ 4) mice at 6 months. Cell counts are
expressed as the density of GFAP-positive cells (cells/mm2). Main effects of genotype were determined by one-way ANOVA, and the source of
reliability was confirmed by post hoc Student’s t-test. Data were considered statistically significant when *P < 0.05, **P < 0.01 and ***P < 0.001.
Data presented as mean 6 SEM. ST ¼ striatum.
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Figure 7 Hippocampal neuroinflammation in L1 and L66 mice. Representative fluorescence images for double labelling of microglia and
astrocytes (A–D). Thirty micrometre sections are stained for Iba1 (green), GFAP (red) and 40,6-diamidino-2-phenylindole (blue) for selected
dentate gyrus sub-regions of the hilus, sub-granular zone, molecular layer, granular layer, hippocampal CA1 region and entorhinal cortex in WT
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A reduction in striatal ChAT was also observed in L1
at 3, 6 and 9 months, data that match that of the human
Alzheimer’s disease brain, where there is a reduction in
ChAT in the ventral and dorsal ST (Boissière et al.,
1997). In addition, a significant reduction in AChE stain-
ing intensity was observed in both cortex and hippocam-
pus of L1 at 3 and 12 months.
In line with the ChAT reduction in L1, hippocampal
AChE levels have been reported to be significantly
reduced in patients with mild cognitive impairment and
early Alzheimer’s disease (Rinne et al., 2003), displaying
robust correlations to cognitive impairment (Shinotoh
et al., 2000; Bohnen et al., 2005). Given the cognitive
phenotype in L1 (Melis et al., 2015), the observed reduc-
tion in AChE levels may explain some of the spatial
learning and memory deficits known for L1 mice.
Survival of basal forebrain cholinergic neurons is entire-
ly dependent on the binding of nerve growth factor to
hippocampal and cortical receptors including tropomyosin
receptor kinase A and p75NTR (Niewiadomska et al.,
2011). An age-dependent reduction in p75NTR was
observed in L1 from 3 months onwards in basal forebrain
regions of the MS, VDB, HDB and nBM. These parallel
post-mortem observations in patients with Alzheimer’s
disease, in which p75NTR is significantly reduced in the
nucleus basalis of Meynert, the equivalent of the murine
nBM (Salehi et al., 2000; Mufson et al., 2002). However,
no age-dependent reduction in ChAT was observed in L1
mice suggesting that ChAT reduction occurs early on and
this pathology remains steady with age.
At the same time, an increase in microglial activation
in the basal forebrain of L1 mice may also be initiated
by a ChAT reduction at 6 months or earlier. Equivalent
studies in rodent models have shown that selective lesion-
ing of the basal forebrain leads to a direct increase in
susceptibility to cognitive deficits induced by acute in-
flammation (Field et al, 2012); therefore, this increase in
microglial activation may also contribute to an explan-
ation of the cognitive deficits observed in L1 at 3 months
of age (Melis et al., 2015). Enhanced neuroinflammation
was confirmed in L1 as a significant increase in the ex-
pression of Iba1 in the VDB, HDB and ST. Our data
suggest that microglial activation in L1 may follow a
cholinergic loss in corresponding basal forebrain regions,
albeit microglial activation was observed at 6 months
only, and was not investigated at 3 months in this study.
However, this could suggest a potential predisposition of
regions affected by cholinergic neuron loss, as being sus-
ceptible to microglial recruitment and activation.
This hypothesis has been explored previously in mice,
where pre-existing cholinergic deficits can result in a pre-
disposition towards inflammatory insult, through up-regu-
lation of inflammatory markers IL-1b, tumour necrosis
factor alpha and IL-6, following selective basal forebrain
lesioning (Field et al., 2012). A significant increase in
microglial marker Iba1 was observed across hippocam-
pus, EC, of L1 mice. Of note is the particularly high ex-
pression of microglia in the SGZ, as this specific area of
the DG is where neurogenesis primarily occurs (van
Praag et al., 2002). Previous studies have suggested that
a disruption in neurogenesis, particularly through neuro-
proliferation observed in the DG, may be potentially
associated with the age-dependent decrease in hippocam-
pal learning and memory in Alzheimer’s disease (Jin
et al., 2004). Specifically, microglia and astrocytes
Figure 7 Continued
mice AT 6 months. Representative images were obtained at 20 magnification. Scale bar, 55 mm. (E–J) Quantification of Iba1 stereological cell
counting from dentate gyrus and hippocampal regions from transgenic L1 (n¼ 7), L66 (n¼ 8) and WT (NMRI, n¼ 8) mice at 6 months. Cell
counts are expressed as Iba1-positive cells (cells/mm2). Quantification of GFAP stereological cell counts is found in Supplementary Fig. 2. Main
effects of genotype for each area were determined using one-way ANOVA, and the source of significance was traced by post hoc Student’s t-tests.
Data were considered statistically significant when *P < 0.05, **P < 0.01 and ***P < 0.001. Data presented as mean 6 SEM. DAPI ¼ 40,6-
diamidino-2-phenylindole.
Figure 8 Quantitative analysis of complement C3 in
striatum with nucleus accumbens (A), hippocampus (B) and
interleukin 1b (C, D) from 6-month-old transgenic L1, L66 and WT
(NMRI) mice at 6 months. For all genotypes, n¼ 3 for striatum and
n¼ 5 for hippocampus. Concentrations were measured by enzyme-
linked immunosorbent assay. Data are presented as mean 6 SEM.
Interactions between groups were determined using one-way
ANOVA and the source of significance explored by post hoc
Newman–Keuls test. **P < 0.01. Data presented as mean 6 SEM.
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influence neurogenesis through the induction of apoptosis
and the negative regulation of neurogenesis via Notch-
mediated signalling pathways (Sierra et al., 2010;
Wilhelmsson et al., 2012). Although not established in
this study, it is conceivable that both microglia and astro-
cyte activation will compromise neurogenesis, thereby
explaining some of the cognitive deficits observed in L1/
L66 from 3 months of age (Melis et al., 2015a). In add-
ition, a significant increase in IL-1b, a marker of acti-
vated microglia, was observed in the hippocampus of L1
mice at 6 months. Heightened expression of pro-inflam-
matory cytokines, such as IL-1b, has been associated pre-
viously with mild cognitive impairment in the brains of
patients with Alzheimer’s disease (Forlenza et al., 2009).
This may be a therapeutic target as the reduction in IL-Ib
attenuated tau pathology in 3Tg-AD mice (Kitazawa
et al., 2011).
Less overlap was observed between the loss of acetyl-
choline in hippocampus and gliosis. Since cholinergic
afferents from the basal forebrain project directly to the
hippocampus (Perez-Lloret and Barrantes, 2016), loss of
cholinergic labelling in basal forebrain neurons was
expected to evoke a secondary inflammatory response in
the hippocampus in L1, but not necessarily in L66. The
fact that L66 has no cholinergic phenotype in the MS,
but expressed strong astrogliosis in the hippocampus, is
therefore intriguing. Previously, it has been shown that
hippocampal astrocytes respond to acetylcholine released
from synaptic terminals, suggesting the possible existence
of cholinergic synapse–astrocyte interactions (Araque
et al., 2002). The data reported here seem to suggest a
dissociation between cholinergic loss in basal forebrain
and inflammatory responses in their target structures. We
confirmed that the lack of Iba1 microglial activation does
not preclude an up-regulation of other neuroinflammatory
markers, especially IL-1b and complement C3.
Previous studies have also shown that levels of micro-
glia are substantially elevated in the brains of ageing
rodents, and this elevation is not necessarily associated
with a cholinergic deficit, particularly within the MS and
VDB (McQuail et al., 2011). Furthermore, no differences
in Iba1 or GFAP morphology were observed in either
basal forebrain or hippocampus of L1 or L66 mice at
6 months. Overall, this suggests that the cholinergic sys-
tem and inflammation may coincide for specific basal
forebrain regions, but that they do not appear to overlap
necessarily in region-specific targets in the above models.
L66 is more FTLD-like
In contrast to L1 mice, L66 exhibited no difference in
total ChAT-IR neuron cell count at 3–9 months in the
basal forebrain (apart from Broca’s band) suggesting rela-
tively intact cholinergic function. This finding supports
the proposed FTLD-like phenotype for these mice (Melis
et al., 2015) and matches the data from patients with
FTLD, in which no significant difference in ChAT
activity, relative to age-matched controls, was reported
(Procter et al., 1999; Bowen et al., 2008, Hirano et al.,
2010). Second, a significant reduction in cortical AChE
was observed as late as 12 months in L66, with no differ-
ence observed in the hippocampus at the same age.
Again, this is reminiscent of patients with FTLD exhibit-
ing no differences in hippocampal AChE levels (Hirano et
al., 2006). Third, no changes in p75NTR staining were
observed in L66 models at 3 or 9 months, suggesting that
neither neuronal cell loss nor loss of cholinergic function
accounts for the motor phenotype or intact spatial learn-
ing phenotype previously observed in these mice (Melis
et al., 2015). The above findings therefore strongly trans-
late to the disease phenotype of FTLD in L66 mice.
In L66, a robust microglial activation was also
observed in basal forebrain and ST. This result is inter-
esting, as none of these regions exhibited any change in
cholinergic neuron density through the measurement of
ChAT activity. The pathway of inflammation in FTLD is
much less understood than in Alzheimer’s disease, al-
though studies in patients with FTLD have revealed an
increase in pro-inflammatory cytokines including tumour
necrosis factor alpha and tumour necrosis factor-b
(Sjögren et al., 2004). In the brain of patients with
FTLD, microglial activation has been widely observed,
using immunohistochemistry, in frontal and temporal cor-
tex (Lant et al., 2014), and in dorsolateral prefrontal cor-
tex and hippocampus (Cagnin et al., 2004).
Our study provides the first indication that microglial
activation in tau Tg L66 mice that mimic FTLD may be
widespread and related to regions affected by tau depos-
ition, such as frontal cortex, EC and hippocampus (Melis
et al., 2015) rather than cholinergic degeneration.
Activated microglia could promote pro-inflammatory acti-
vation of astrocytes (Lian et al., 2016). Interleukin-1a
and IL-1b, microglia-derived acute phase cytokines, and
activated astrocytes are known to up-regulate the expres-
sion of the astrocyte-derived complement protein C3
(Maranto et al., 2008). These cytokines form complex
interactions that may be capable of self-propagation, thus
leading to chronic overexpression of glial cytokines with
neurodegenerative consequences (Mrak et al., 1995). Self-
propagation may be facilitated by means of several rein-
forcing feedback loops. For instance, microglia express
the C3a receptor (Zhang et al., 2014) and their function
could be impacted by astrocytic release of C3. Directly
activated microglia release IL-1 and stimulate the astro-
cyte complement system, leading to additional microglial
activation through C3a receptors. Thus, a microglial IL-
1b-astrocytic C3–microglial C3a receptor positive feed-
back loop could govern inflammatory dynamics and tau
neuropathology. These interactions with tau remain
poorly understood, but available data suggest that the se-
verity of both astrogliosis and microglial activation is
linked to tau species and to the severity of aggregated
tau.
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Finally, both L1 and L66 show increased GFAP- and
Iba1-IR cells in the basal forebrain HDB and SGZ of the
DG. In FTLD, astrocytosis has been reported in the ab-
sence of neuronal loss (Broe et al., 2004), whilst astrocyt-
ic pathology in Alzheimer’s disease is directly associated
in regions exhibiting neuronal loss (Forman et al., 2005).
Summary
Collectively, two independent studies have observed sig-
nificant loss of cholinergic staining in the basal forebrain
in L1, whilst there is also a sub-regional microglial acti-
vation. These observations may help explain in part the
cognitive deficits observed in L1 and confirm the
Alzheimer’s disease-like phenotype. By contrast, L66
exhibited a relatively intact cholinergic system but pre-
sented with a robust and widespread microglial activation
uncorrelated with cholinergic pathology.
Given the differences in the human tau species
expressed in these two mouse models, the overexpression
of two different forms of tau can lead to two very dis-
tinct and robust phenotypes that show characteristic fea-
tures of Alzheimer’s disease-like and FTLD-like
tauopathies. Not only does L1 mimic an age-dependent,
Braak-like spread of tau pathology, it also features a loss
of cholinergic function that is characteristic of
Alzheimer’s disease. This differs from L66, with its more
robust and widespread tau pathology with considerably
more overlap of inflammation, that make it representative
of FTLD.
Supplementary material
Supplementary material is available at Brain
Communications online.
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